Compare Amphastar Pharmaceuticals Inc (AMPH) vs Commvault Systems Inc (CVLT) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

Commvault (CVLT) trades at $150.57, down 0.57% on the day, with a bullish technical signal from moving averages and strong support at $146. The company reported revenue of $995.62M in 2025, with net income of $76.11M, though earnings have been mixed with two beats and one miss in recent quarters. A high P/E of 95.3 indicates premium valuation, while ROE stands at 42.49%. Recent news highlights a securities class action lawsuit with a July 17, 2026 deadline.

Outlook is mixed: analyst consensus is bullish with 54.55% buy ratings and a $128.75 price target, but legal risks and high valuation pose headwinds. Revenue growth to $1.2B in 2026 offers upside, yet profit margin compression and lawsuit uncertainty require caution for investors seeking stability.